Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “MAMMAE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3Linked to original sources
PubMed1987

Altered expression of glycosaminoglycans in metastatic 13762NF rat mamma adenocarcinoma cells.

A difference in the expression and metabolism of sulfated glycosaminoglycans between rat mammary tumor cells derived from a primary tumor and those from its metastatic lesions has been observed. Cells from the primary tumor possessed about equal quantities of chondroitin sulfate and heparan sulfate on their cell surfaces but released fourfold more chondroitin sulfate than heparan sulfate into their medium. In contrast, cells from distal metastatic lesions expressed approximately 5 times more heparan sulfate than chondroitin sulfate in both medium and cell surface fractions. This was observed to be the result of differential synthesis of the glycosaminoglycans and not of major structural alterations of the individual glycosaminoglycans. The degree of sulfation and size of heparan sulfate were similar for all cells examined. However, chondroitin sulfate, observed to be only chondroitin 4-sulfate, from the metastases-derived cells had a smaller average molecular weight on gel filtration chromatography and showed a decreased quantity of sulfated disaccharides upon degradation with chondroitin ABC lyase compared to the primary tumor derived cells. Major qualitative or quantitative alterations were not observed for hyaluronic acid among the various 13762NF cells. The metabolism of newly synthesized sulfated glycosaminoglycans was also different between cells from primary tumor and metastases. Cells from the primary tumor continued to accumulate glycosaminoglycans in their medium over a 72-h period, while the accumulation of sulfated glycosaminoglycans in the medium of metastases-derived cells showed a plateau after 18-24 h. A pulse-chase kinetics study demonstrated that both heparan sulfate and chondroitin sulfate were degraded by the metastases-derived cells, whereas the primary tumor derived cells degraded only heparan sulfate and degraded it at a slower rate.(ABSTRACT TRUNCATED AT 250 WORDS)

Adenocarcinoma↗
PubMed1979

Effects of progesterone on mammary carcinogenesis by DMBA applied directly to rat mammae.

The effects and site(s) of action of progesterone on DMBA mammary carcinogenesis in the rat, when a small dose of the carcinogen was applied directly to the inguinal mammary gland, were investigated. No reduction in tumour yield was apparent when progesterone was administered s.c. for 18 days before dusting DMBA. This finding contrasts with a previously reported inhibitory effect on carcinogenesis when hormone treatment was followed by intragastric administration of DMBA. When progesterone injections were begun either 2 days before or 2 days after direct application of DMBA, and were continued until the end of the experiment (135 or 195 days) an enhancement in carcinogenesis was observed similar to that previously demonstrated after gastric intubation of DMBA. These findings, together with previously reported observations, suggest that progesterone may exert its inhibitory effect on carcinogenesis by acting at a site outside the breast, perhaps on the liver. However, it is likely that the hormone acts directly on the mammary tissue to exert its enhancing effect on tumorigenesis.

9,10-Dimethyl-1,2-benzanthracene↗
PubMed1990

[Therapy and prognosis of small breast cancers. Comparison of subcutaneous mastectomy procedures with ablatio mammae].

A retrospective clinical study included 1283 patients with breast cancer. 307 of 762 tumours with known diameter (mm) were classified as stage pT1 (TNM, 70). Four groups were formed to compare the prognosis in subgroups of pT1 cancers: 0-5 mm (n = 22), 6-9 mm (n = 22), 10 mm (n = 53) and 11-20 mm (n = 210). A comparison of three types of surgery was made: Radical subcutaneous mastectomy (12), bilateral modified subcutaneous mastectomy (10, 11), and modified radical mastectomy (Auchincloss, 3). Both forms of subcutaneous mastectomy were combined with adjuvant postoperative radiotherapy to the side of the tumour. In this trial, patients were younger at diagnosis than usually stated in the literature. Small breast cancers had the same localisation and histology as large ones. Axillary lymph node metastases were identified from a tumour diameter of 6 mm upwards. Bilateral tumours were seen in 2 of 22 patients with tumours less than or equal to 5 mm. Multifocal growth was observed also in the same size range. Histologically different simultaneous invasive unilateral cancers were seen starting at a diameter of 8 mm of the larger tumour. Systemic metastases were observed in tumours of 10 mm in diameter. Local recurrences occurred in breast cancers with a diameter of 2 mm and more. There were no recurrences in the area of the nipple or areola in pT1 cancers. Small breast cancers did not appear to be biologically different from larger lesions. No prognostic subgroups of pT1 were evident beyond the established TNM staging. Disease-free survival was not significantly different between the three surgical approaches. Local recurrence was significantly less frequent after breast-conserving surgery. A negative influence of local recurrence on the prognosis was observed to a similar extent irrespective of the type of surgery. The concept of "minimal breast cancer" suggesting ablative surgery for a heterogeneous group of preinvasive and small invasive lesions is outdated. The different forms of subcutaneous mastectomy are a therapeutic alternative in the context of breast-conserving surgery of small infiltrating breast cancers. Especially the modified subcutaneous mastectomy (Beller) combines a good cosmetic result without prognostic impairment and with a potential reduction of the risc of contralateral breast cancer. Further potential applications include prophylactic treatment of high-risk patients with preinvasive lesions.

Breast Neoplasms↗
PubMedDate not supplied

[Mamma aberrata in the axilla--case report and review of literature].

BACKGROUND: Polymastia is a common developmental abnormality of the breast. Supernumerary breast tissue usually develops along the mammary line. Polymastia in the most woman has been diagnosed by hormonal influence, cancer or other pathologic changes. PATIENTS: We report a localisation of polymastia in the axilla of a 14 year old girl. The lesion was removed to microscopic examination and to eliminate the possibility of a malignancy developing.

Adolescent↗
PubMed2002

ROBITOM-robot for biopsy and therapy of the mamma.

MR-Mammography reaches a high sensitivity in detecting breast carcinomas of 3 mm in size at least. In cooperation with the Institute of Diagnostic and Interventional Radiology of the Friedrich-Schiller-University of Jena, a manipulator has been developed by the IMB, which combines the advantages of MRM imaging with a minimal invasive biopsy and a possible subsequent therapy. Referring to this ROBITOM I was introduced in November 1999 as worldwide first, precise operating manipulator system in the ISO center of a closed MR, at RSNA in Chicago. Clinical trials started at 22. November 2000. The experiences and results of these tests were brought into the following prototype ROBITOM II, that is currently developed at the IMB. The completion of this Prototype is planned at the end of 2002.

Biopsy↗
PubMed2002

Automatic image matching for breast cancer diagnostics by a 3D deformation model of the mamma.

X-ray mammograms and MR volumes provide complementary information for early breast cancer diagnosis. The breast is deformed during mammography, therefore the images can not be compared directly. A registration algorithm is investigated to fuse the images automatically. A finite element simulation was applied to a MR image of an underformed breast and compared to a compressed breast using different tissue models and boundary conditions. Based on the results a set of patient data was registered. To archive the requested accuracy distinguishing between the different tissue types of the breast was not necessary. A linear elastic model was sufficient. It was possible to simulate the deformation with an average deviation of approximately of the size of a voxel in the MRI data and retrieve the position of a lesion with an error of 3.8 mm in the patient data.

Breast↗
PubMed1977

Stereotaxic instrument for needle biopsy of the mamma.

A stereotaxic instrument is described which facilitates percutaneous needle biopsy of the breast for microscopic diagnosis. The instrument consists of an x-ray tube mounted on a hinged arm, pivoting stand, patient table, compression device with film holder and scale system, coordinate-controlled puncture device with separate stand, biopsy instrument, and calculator. The sampling site can be located at a precision within +/- 1 mm. The instrument can also be used for positioning of metal and dye indicators for guiding surgery and for postoperative identification of excised tumors.

Biopsy, Needle↗
PubMed1982

Effects of progesterone on mammary carcinogenesis when various doses of DMBA were applied directly to rat mammae.

To investigate the suggestion that progesterone acts directly on the mammary gland to inhibit carcinogenesis, doses of 500, 100 or 30 microgram of DMBA were applied directly to inguinal mammary glands of 50 d old rats which either received no other treatment or were injected with progesterone (3 mg/d) s.c. for 18 d before dusting the carcinogen. Progesterone pretreatment did not inhibit mammary carcinogenesis in rats dusted with 500 microgram or DMBA. When smaller doses of DMBA (100 microgram or less) were applied, hormone pretreatment markedly reduced carcinogenesis, the inhibitory effect being statistically significant in the group dusted with the smallest dose of carcinogen. As the dusting technique eliminated any observable systemic effects of the carcinogen, it is concluded that the results support the suggestion that progesterone acts directly on the mammary gland to inhibit carcinogenesis and that this effect can be over-ridden if a large enough dose of DMBA (somewhere between 100 and 500 micrograms) is applied. The importance of carcinogen dose to resulting tumour yield was clearly shown by the significant descending gradation in tumour incidences and gradual lengthening of average tumour latent periods in the 3 control groups with decreasing DMBA dose, as well as in the 3 hormone-pretreated groups.

9,10-Dimethyl-1,2-benzanthracene↗